Sun Pharmaceutical Industries

524715 · BSE · INR

₹1,810.00

Close · October 1, 2026

At a glance

Revenue growth
+11.19%
FY to Mar 2026 vs FY to Mar 2025
Net income growth
+5.04%
FY to Mar 2026 vs FY to Mar 2025
Net margin
19.6%
FY to Mar 2025: 20.8%

Financial data

Amounts in millions of INR; per-share values in INR; shares in millions.

Income statement · Quarterly
ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue152,999146,118155,205144,783138,514129,588136,755132,914126,528119,829123,807121,924
Cost of revenue29,63237,36129,45129,82728,14834,48327,40526,94226,75431,60027,36927,871
Gross profit123,367108,757125,754114,956110,36695,106109,349105,97299,77388,22996,43894,053
Selling, general and administrative32,27230,59828,92027,64828,01725,66325,52324,77724,54623,72823,63323,644
Operating income35,57028,10240,62233,67133,72128,55835,61831,85030,02925,31027,30125,807
EBIT35,57028,10240,62233,67133,72128,55835,61831,85030,02925,31027,30125,807
EBITDA42,32434,85746,52940,82139,62734,46441,50838,25535,91931,19933,16532,227
Interest expense997859784999748491515692615736347493
Pre-tax income40,89235,37342,07241,55531,63032,47634,71836,04534,12828,07729,92927,752
Income tax11,8808,2768,26110,3058,70210,9375,5895,6725,5231,4894,3233,901
Net income28,94827,14033,68831,18022,78621,49929,03430,40228,35626,54625,23823,755
Net income to common shareholders28,94827,14033,68831,18022,78621,49929,03430,40228,35626,54625,23823,755
Basic EPS12.1011.3014.0013.009.509.0012.1012.7011.8011.1010.509.90
Diluted EPS12.1011.2614.0013.009.509.0012.1012.7011.8011.0910.509.90
Average shares (basic)2,3922,4022,4062,3982,3992,3892,3992,3942,4032,3922,4042,400
Average shares (diluted)2,3922,4022,4062,3982,3992,3892,3992,3942,4032,3922,4042,400
Dividend per share—5.0011.00——5.5010.50——5.008.50—